[go: up one dir, main page]

MX2017004828A - Composicion oftalmica que comprende ciclosporina y trehalosa. - Google Patents

Composicion oftalmica que comprende ciclosporina y trehalosa.

Info

Publication number
MX2017004828A
MX2017004828A MX2017004828A MX2017004828A MX2017004828A MX 2017004828 A MX2017004828 A MX 2017004828A MX 2017004828 A MX2017004828 A MX 2017004828A MX 2017004828 A MX2017004828 A MX 2017004828A MX 2017004828 A MX2017004828 A MX 2017004828A
Authority
MX
Mexico
Prior art keywords
ophthalmic composition
cyclosporine
trehalose
ophthalmoxerosis
same
Prior art date
Application number
MX2017004828A
Other languages
English (en)
Other versions
MX379500B (es
Inventor
Hwan Lim Jong
Woong Ko Dae
Kwan NAM Seung
Woon Hong Sung-
Sun Ahn Mi
Kyu HWANG Deok-
Mok Kim Yeong-
An Um Key-
Original Assignee
Huons Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Huons Co Ltd filed Critical Huons Co Ltd
Publication of MX2017004828A publication Critical patent/MX2017004828A/es
Publication of MX379500B publication Critical patent/MX379500B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13Cyclosporins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016Disaccharides, e.g. lactose, lactulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a una composición oftálmica que comprende ciclosporina y trehalosa como componentes efectivos, un método para producir el mismo, un método para prevenir, mejorar o tratar el fallo causado por oftalmoxerosis administrando el mismo, y un uso para el mismo. La composición oftálmica de acuerdo con la presente invención tiene una combinación de efectos superiores sobre la oftalmoxerosis, que puede ser causada por diversos factores tales como aire seco, inflamación, conservantes, etc., y se coloca en una variedad de estados o condiciones.
MX2017004828A 2014-10-17 2015-10-19 Composición oftálmica que comprende ciclosporina y trehalosa. MX379500B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020140141089A KR101587412B1 (ko) 2014-10-17 2014-10-17 사이클로스포린 및 트레할로스를 포함하는 안과용 조성물
PCT/KR2015/011048 WO2016060532A1 (ko) 2014-10-17 2015-10-19 사이클로스포린 및 트레할로스를 포함하는 안과용 조성물

Publications (2)

Publication Number Publication Date
MX2017004828A true MX2017004828A (es) 2017-07-20
MX379500B MX379500B (es) 2025-03-10

Family

ID=55308741

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017004828A MX379500B (es) 2014-10-17 2015-10-19 Composición oftálmica que comprende ciclosporina y trehalosa.

Country Status (14)

Country Link
US (1) US10039803B2 (es)
EP (1) EP3213763B1 (es)
JP (1) JP6611803B2 (es)
KR (1) KR101587412B1 (es)
CN (1) CN106999543B (es)
AU (1) AU2015331089B2 (es)
BR (1) BR112017007813A2 (es)
ES (1) ES2773641T3 (es)
MX (1) MX379500B (es)
PH (1) PH12017500615A1 (es)
RU (1) RU2700927C2 (es)
SA (1) SA517381318B1 (es)
SG (1) SG11201704695WA (es)
WO (1) WO2016060532A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3280412T (lt) * 2015-04-09 2019-11-25 Laboratori Baldacci Spa Pirolidono karboksirūgštis (pkr), skirta naudoti oftalmologijoje
KR20180030323A (ko) * 2016-09-13 2018-03-22 주식회사 코아팜바이오 사이클로스포린의 안구필름 제형
KR102268319B1 (ko) * 2016-12-29 2021-06-23 (주)휴온스 지속성 점안제 조성물
ES3054066T3 (en) * 2017-06-09 2026-01-29 Omnivision Gmbh Composition for the treatment of dry eye
US10702578B2 (en) 2017-08-02 2020-07-07 Shilpa Medicare Limited Ophthalmic compositions of cyclosporine
CN113069556B (zh) * 2021-04-12 2022-04-08 青岛大学附属医院 一种枝接那他霉素的氧化海藻酸纤维膜及其制备方法
CN113262235B (zh) * 2021-04-25 2022-10-21 自然资源部第三海洋研究所 新琼寡糖在治疗眼科疾病方面的新用途
KR102764433B1 (ko) * 2022-03-28 2025-02-07 경북대학교 산학협력단 태반유래 양막상피세포에서 포집된 세포외 소포 기반의 안과용 국소 약물전달체
WO2023229332A1 (ko) * 2022-05-24 2023-11-30 줄리아 연구소 주식회사 트레할로스를 포함하는 망막 질환 또는 퇴행성 뇌 질환의 예방, 개선 또는 치료용 건강식품 조성물 및 약학적 조성물

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6290991B1 (en) * 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
CA2355814C (en) * 2000-09-14 2010-06-29 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Pharmaceutical composition for ophthalmic use
JP4982643B2 (ja) * 2000-09-14 2012-07-25 株式会社林原 眼科用医薬組成物
DE102006051512A1 (de) * 2005-12-06 2007-06-14 Pari GmbH Spezialisten für effektive Inhalation Pharmazeutische Medikamentenzusammensetzungen mit Cyclosporin
US20080146497A1 (en) * 2006-07-25 2008-06-19 Graham Richard S Cyclosporin Compositions
CN101049504B (zh) * 2007-04-05 2010-05-19 广州立恩生物科技有限公司 一种脂质体药物载体及其制备方法
CA3014633C (en) * 2007-10-08 2022-05-17 Aurinia Pharmaceuticals Inc. Ophthalmic compositions comprising calcineurin inhibitors or mtor inhibitors
US20110070293A1 (en) * 2009-09-23 2011-03-24 Javeri Indu Methods for the Preparation of Liposomes Comprising Docetaxel
TWI531377B (zh) * 2011-02-08 2016-05-01 艾伯維有限公司 骨關節炎及疼痛之治療
US20130029919A1 (en) 2011-07-26 2013-01-31 Allergan, Inc. Two part formulation system for opthalmic delivery
KR101211902B1 (ko) 2012-04-30 2012-12-13 주식회사 휴온스 사이클로스포린 함유 무자극성 나노에멀젼 안약 조성물
HRP20230559T1 (hr) * 2012-08-24 2023-09-15 Sun Pharmaceutical Industries Limited Oftalmička formulacija polioksil lipida ili polioksil masne kiseline i tretman očnih stanja
KR101492447B1 (ko) * 2013-05-20 2015-02-23 주식회사태준제약 사이클로스포린을 함유하는 나노에멀젼 점안 조성물 및 그의 제조 방법
WO2015013330A2 (en) * 2013-07-22 2015-01-29 Kineta One, Llc Ophthalmic uses of toxin-based therapeutic peptides and pharmaceutical compositions thereof
CA2955037A1 (en) * 2014-07-18 2016-01-21 Allergan, Inc. Suspension compositions of cyclosporin a for subconjunctival and periocular injection

Also Published As

Publication number Publication date
JP6611803B2 (ja) 2019-11-27
EP3213763A1 (en) 2017-09-06
RU2017116974A (ru) 2018-11-21
RU2017116974A3 (es) 2019-04-17
CN106999543B (zh) 2021-01-05
EP3213763B1 (en) 2020-01-08
ES2773641T3 (es) 2020-07-13
SA517381318B1 (ar) 2020-09-09
WO2016060532A1 (ko) 2016-04-21
BR112017007813A2 (pt) 2017-12-19
MX379500B (es) 2025-03-10
SG11201704695WA (en) 2017-07-28
US20170224766A1 (en) 2017-08-10
AU2015331089B2 (en) 2020-10-15
JP2017531022A (ja) 2017-10-19
EP3213763A4 (en) 2018-07-18
AU2015331089A1 (en) 2017-06-08
CN106999543A (zh) 2017-08-01
US10039803B2 (en) 2018-08-07
RU2700927C2 (ru) 2019-09-24
PH12017500615B1 (en) 2017-09-04
KR101587412B1 (ko) 2016-01-21
PH12017500615A1 (en) 2017-09-04

Similar Documents

Publication Publication Date Title
MX2017004828A (es) Composicion oftalmica que comprende ciclosporina y trehalosa.
CO2018006714A2 (es) 3-azabiciclo[3.1.0]hexanos sustituidos como inhibidores de cetohexoquinasa
CL2018003588A1 (es) Uso de inhibidores de miostatina y terapias de combinación.
MX2018005829A (es) Composiciones para tratar el cabello.
AR096478A1 (es) Composiciones para el tratamiento de superficie que comprenden tintes fotocromáticos
MX2016013034A (es) Composicion detergente.
CO2017005034A2 (es) Tratamiento de convulsiones con fosfatasa alcalina recombinante
CL2016000055A1 (es) Métodos para tratar o prevenir afecciones oftalmológicas
MX2019005402A (es) Terapias de combinacion del inhibidor de arginasa.
CL2016000326A1 (es) Composiciones y método para tratar condiciones asociadas con el complemento
CR20150376A (es) Compuestos sustituidos de pirrolopirimidina, compuestos de los mismos y metodos de tratamiento con los mismos
UY36703A (es) Composiciones y métodos para la administración de un polinucleótido en una planta
EA202090632A1 (ru) Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов
BR112016023851A2 (pt) ?composição de revestimento de duas partes e método para revestir uma superfície?
CR20170219A (es) Inhibidores del bromodominio
MX2015011281A (es) Composiciones de inh-c1 y metodos para la prevencion y el tratamiento de trastornos asociados con la deficiencia del inhibidor de c1 esterasa.
MX2015016627A (es) Vacuna para la malaria.
CL2013003349A1 (es) Composicion que comprende una combinacion sinergica de un fungicida polienico y por lo menos un lipopeptido; y metodo para controlar patogenos fungicos.
DOP2016000336A (es) Derivados de isoindolina para uso en el tratamiento de una infeccion viral
CL2015002897A1 (es) Inhibidores de bace1
MX2016013236A (es) Formulacion inmunosupresora.
MX374385B (es) Apilimod para uso en el tratamiento de melanoma.
CL2016001210A1 (es) Análogos de bicalutamida o (s)- bicalutamida como compuestos activadores de la exocitosis para su uso en el tratamiento de un desorden de acúmulo lisosomal o glucogenosis.
MX383944B (es) Composiciones para el cuidado personal.
MX2017007000A (es) Composiciones que comprenden acido 15-hidroxieicosapentaenoico (15-hepe) y metodos para tratar o prevenir la fibrosis usando las mismas.